Cargando…
Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)
INTRODUCTION: The COVID-19 pandemic has major impact of healthcare systems, including cancer care pathways. The aim of this work is to discuss in a multidisciplinary approach the therapeutic and/or strategies adaptations for patients treated for a digestive cancer during the European second wave of...
Autores principales: | Tougeron, David, Michel, Pierre, Lièvre, Astrid, Ducreux, Michel, Gaujoux, Sébastien, Guiu, Boris, Huguet, Florence, Lecomte, Thierry, Lepage, Côme, Louvet, Christophe, Maggiori, Léon, Mariani, Pascale, Aparicio, Thomas, Bouché, Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836265/ https://www.ncbi.nlm.nih.gov/pubmed/33341421 http://dx.doi.org/10.1016/j.dld.2020.11.029 |
Ejemplares similares
-
COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)
por: Di Fiore, Frederic, et al.
Publicado: (2020) -
Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER)
por: Tougeron, David, et al.
Publicado: (2021) -
Vaccination contre la COVID-19 des patients atteints de cancer solide : revue et préconisations d’un inter-groupe oncologique français (CGO, TNCD, UNICANCER)
por: Tougeron, David, et al.
Publicado: (2021) -
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)
por: Kim, Stefano, et al.
Publicado: (2017) -
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
por: André, Thierry, et al.
Publicado: (2023)